The current quality and requirements of prehospital and emergency care in Indonesia and Malaysia: a cross-sectional multicenter survey - Tokita, Akio; Nunokawa, Hanako; Liu, Keibun; Iwamoto, Yuta; Sonoo, Tomohiro; Hara, Konan; Nakajima, Mikio; Fukaguchi, Kiyomitsu; Takeda, Takanori; Sanip, Amirudin; Juzar, Dafsah A.; Harvendhar Singh, Gurjeet Singh a/l; et al. (medRxiv, 2023)
Background Rapid economic growth in Southeast Asian countries has led to a significant gap between supply and demand of emergency care, which may negatively affect the health outcomes of local populations. The purpose of this study was to identify current challenges faced by emergency care systems in Indonesia and Malaysia.Methods An online survey was conducted between August and November 2022. Survey participants consisted of emergency department (ED) doctors, nurses, and other medical staff in 11 hospitals in Indonesia and Malaysia. The survey collected information on respondents’ characteristics, factors associated with the quality of prehospital or ED care, missing clinical information, and factors associated with patients’ length of stay at the ED.Results A total of 83 and 109 respondents from Indonesia and Malaysia, respectively, answered the survey. The most important factor affecting prehospital care quality in both countries was “inadequate amount of clinical information from the ambulance.” The most important factor affecting ED care quality was “crowdedness in the emergency room during night shifts.” The clinical information most frequently missing was family history, followed by estimated time of arrival to the hospital or medication history. The primary factor affecting the length of ED stay was diagnostic studies and their turnaround time.Conclusions This study identified common challenges in the emergency care systems of Indonesia and Malaysia. Our findings highlight the importance of recognizing both common and country-specific challenges to improve the quality of emergency care in Southeast Asia.Competing Interest StatementTomohiro Sonoo is the CEO of TXP Medical and holds related stock shares. Konan Hara received funding, study materials, medical writing support, and article processing charges from TXP Medical Co. Ltd. He also received consulting fees, honoraria for educational events, and holds stock options in the company. Dafsah Arifa Juzar serves as Secretary General of the Indonesian Heart Society from 2019 to 2022 and as Vice Secretary General from 2022 to 2025. The remaining authors report no conflicts of interest.Funding StatementThis study was funded by 2022 Healthcare Industry International Development Promotion Project, Ministry of Technology and Innovation and Medical Excellence Japan; Project for Promotion of International Development of Medical Technology, National Center for Global health and Medicine and Ministry of Health Labor and Welfare; Asia DX Promotion Project in ASEAN, Ministry of Technology and Innovation and The Japan External Trade Organization (JAA220803002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of TXP Medical. Co. Ltd. waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.